• Exozymes reported an optimized N-trans-caffeoyltyramine process that lifted manufacturing productivity by 10x versus its earlier pilot-scale baseline.
• NCT output rose about 67% per liter versus the prior 100-liter pilot run, supporting higher commercial-scale throughput.
• Reaction time fell more than 80%, improving time-in-tank economics and capacity utilization for future manufacturing partners.
• Internal cost assessments show estimated manufacturing cost equivalent down more than 100x from the first NCT process version.
• Focus shifted to simplifying operations and preparing technology transfer to commercial partners to move from pilot validation toward scalable production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.